Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis
- 23 August 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Cystic Fibrosis
- Vol. 20 (2), 243-249
- https://doi.org/10.1016/j.jcf.2020.07.017
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Canada
This publication has 29 references indexed in Scilit:
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRThe New England Journal of Medicine, 2015
- Future trends in cystic fibrosis demography in 34 European countriesEuropean Respiratory Journal, 2015
- A contemporary survival analysis of individuals with cystic fibrosis: a cohort studyEuropean Respiratory Journal, 2014
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEuropean Respiratory Journal, 2012
- Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosisEuropean Respiratory Journal, 2011
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationThe New England Journal of Medicine, 2011
- Dynamic Microsimulation Models for Health OutcomesMedical Decision Making, 2010
- Multiple-Breath Washout as a Marker of Lung Disease in Preschool Children with Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Developing Cystic Fibrosis Lung Transplant Referral Criteria Using Predictors of 2-Year MortalityAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Determinants of Mortality from Cystic Fibrosis in Canada, 1970-1989American Journal of Epidemiology, 1996